Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis

Janssen Research& Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news